• Tomivosertib Suppresses Human DRG Ectopic Activity

  2026-08-31

  Li et al. tested the MNK inhibitor tomivosertib directly in cultured human dorsal root ganglion neurons obtained during spinal surgery. At 25 nM, the compound rapidly and reversibly reduced spontaneous activity in neurons associated with painful dermatomes, while altering eIF4E phosphorylation and electrophysiological properties.

• JSH-23: NF-κB Inhibitor Workflow

  2026-08-30

  JSH-23 enables pathway-level testing of NF-κB p65 nuclear localization and transcription without directly blocking IκB degradation. This makes it useful for macrophage inflammation research, pathway-discrimination studies, airway infection assays, and translational kidney-injury models.

• H. pylori–HNF4A Silencing Drives Gastric Cancer

  2026-08-29

  A 2025 Cell Death and Disease study identifies promoter hypermethylation of HNF4A as a mechanistic link between Helicobacter pylori infection, epithelial polarity loss, EMT activation, and gastric cancer progression. Its integrated clinical, single-cell, cellular, and in vivo evidence positions HNF4A methylation as a testable axis in cancer epigenetics and gastric tumor biology.

• Amikacin Disulfate: From Ribosome to Assay Design

  2026-08-28

  Amikacin disulfate is a mechanistically informative 16S rRNA-targeting antibiotic for studying bacterial protein synthesis suppression and resistance. This article connects ribosome-centered assays with orthogonal protein-binding methods, showing how to separate molecular binding, structural change, and functional loss.

• Reparixin: From IL-8 Biology to Translational Proof

  2026-08-28

  A translational framework for using Reparixin, a CXCR1/2 inhibitor, to connect MRSA extracellular-vesicle signaling with tumor biology, neutrophil behavior, and tissue injury while maintaining clear experimental boundaries.

• Salinomycin: Measuring HCC Drug Response Precisely

  2026-08-28

  Salinomycin is a polyether ionophore antibiotic whose effects in hepatocellular carcinoma models require more than a single viability readout. This article presents an assay strategy that separates growth arrest, cell death, ion-homeostasis changes, and pathway modulation for more interpretable research conclusions.

• Carboplatin Workflows for DNA Damage Research

  2026-08-27

  Build reproducible Carboplatin dose–response, DNA synthesis, and resistance assays across ovarian, lung, and triple-negative breast cancer models. The workflow pairs practical formulation guidance with a mechanistic strategy for studying cancer stem-like cells and FZD1/7-linked resistance.

• DAPI and the Microbiome: From Nuclei to Translation

  2026-08-26

  The Prevotella copri–IPyA–UHRF1–AMPK axis reframes breast cancer progression as a microbiome-linked metabolic problem. DAPI adds a practical phenotypic layer, helping translational teams connect nuclear integrity, cell fate, and mechanistic pathway studies without overstating what a DNA stain can prove.

• Coelenterazine for Brain–Kidney Reporter Design

  2026-08-26

  Coelenterazine can do more than generate luciferase light: it helps researchers separate reporter activity, oxidative chemistry, and physiological outcome. This article develops an assay-design framework inspired by brain–kidney axis research and defines where ROS readouts are informative—and where they are not.

• Ridaforolimus in Cancer and Senescence Assays

  2026-08-26

  Ridaforolimus, also called Deforolimus or MK-8669, provides a precise way to interrogate mTOR-dependent growth, metabolism, VEGF output, and treatment response. This practical guide connects concentration-controlled cancer assays with machine-learning-inspired senescence workflows while emphasizing selectivity controls and troubleshooting.

• Palonosetron for Chemotherapy-Induced Nausea and Vomiting

  2026-08-25

  Ruhlmann and Herrstedt’s review explains why palonosetron became clinically distinctive among 5-HT3 receptor antagonists: it combines prolonged exposure and high receptor affinity with allosteric binding and positive cooperativity. The authors connect these pharmacologic properties with clinical evidence on acute and delayed chemotherapy-induced nausea and vomiting, while emphasizing that receptor-level differences matter only when they improve patient outcomes.

• Carboplatin Response: From Dose to Biology

  2026-08-24

  Carboplatin is a platinum-based DNA synthesis inhibitor whose apparent activity depends on both dose and cancer model architecture. This guide translates recent 2D-versus-3D proteomic findings into practical assay decisions for preclinical oncology research.

• PXR Activation, Liver Regeneration, and CYP Activity

  2026-08-24

  Bi et al. show that activating pregnane X receptor (PXR) in rats can couple liver enlargement and post-hepatectomy regeneration with increased activity of major drug-metabolizing CYP enzymes. By combining a partial-hepatectomy model, a CYP probe-drug cocktail, plasma pharmacokinetics, and hepatic protein analysis, the study distinguishes restoration of liver mass from functional changes in drug disposition.

• SM-102: A Decision Framework for mRNA LNPs

  2026-08-23

  SM-102 is more than an ionizable lipid ingredient: it is a useful test case for connecting chemical handling, LNP design, and assay interpretation. This evidence-driven guide explains how to evaluate SM-102 in mRNA delivery studies without overstating results from predictive models or single-animal comparisons.

• Epoxomicin Proteasome Inhibitor Workflow

  2026-08-22

  Epoxomicin provides a selective, irreversible way to interrogate proteasome-dependent protein turnover during ER stress and proteostasis failure. This practical guide connects dose design, degradation assays, UBR1/UBR2 biology, and troubleshooting for more reproducible ubiquitin-proteasome pathway research.

8560 records 1/571 page Next 12345 下5页 Last page